ArticleBMC medical genomics2008
Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data.
Article in BMC medical genomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer.Breast cancer research : BCR · 2023Trial
- Article
- Identification of immune-related gene signature for non-small cell lung cancer patients with immune checkpoint inhibitors.Heliyon · 2024Article
- EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer.BMC medical genomics · 2021Article
- SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets.BMC genomics · 2021Article
- A Clinicogenetic Prognostic Classifier for Prediction of Recurrence and Survival in Asian Breast Cancer Patients.Frontiers in oncology · 2021Article
- Elevated EXO1 expression is associated with breast carcinogenesis and poor prognosis.Annals of translational medicine · 2021Article
- Pathway Mutations in Breast Cancer Using Whole-Exome Sequencing.Oncology research · 2020Article
- Weighted gene expression profiles identify diagnostic and prognostic genes for lung adenocarcinoma and squamous cell carcinoma.The Journal of international medical research · 2020Article
- Gene relevance based on multiple evidences in complex networks.Bioinformatics (Oxford, England) · 2020Article
- An integrative multi-omics network-based approach identifies key regulators for breast cancer.Computational and structural biotechnology journal · 2020Article
- Genes and functions from breast cancer signatures.BMC cancer · 2018Article
- Functional characterization of breast cancer using pathway profiles.BMC medical genomics · 2014Article
- Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer.British journal of cancer · 2014Article
- Integration and analysis of genome-scale data from gliomas.Nature reviews. Neurology · 2011Review
- Predictive Power Estimation Algorithm (PPEA)--a new algorithm to reduce overfitting for genomic biomarker discovery.PloS one · 2011Article
- Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.Breast cancer research : BCR · 2010Article
- [Genome-wide expression profiling as a clinical tool: are we there yet?].Der Pathologe · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNumerous studies have used microarrays to identify gene signatures for predicting cancer patient clinical outcome and responses to chemotherapy. However, the potential impact of gene expression profiling in cancer diagnosis, prognosis and development of personalized treatment may not be fully exploited due to the lack of consensus gene signatures and poor understanding of the underlying molecular mechanisms.
methodsWe developed a novel approach to derive gene signatures for breast cancer prognosis in the context of known biological pathways. Using unsupervised methods, cancer patients were separated into distinct groups based on gene expression patterns in one of the following pathways: apoptosis, cell cycle, angiogenesis, metastasis, p53, DNA repair, and several receptor-mediated signaling pathways including chemokines, EGF, FGF, HIF, MAP kinase, JAK and NF-kappaB. The survival probabilities were then compared between the patient groups to determine if differential gene expression in a specific pathway is correlated with differential survival.
resultsOur results revealed expression of cell cycle genes is strongly predictive of breast cancer outcomes. We further confirmed this observation by building a cell cycle gene signature model using supervised methods. Validated in multiple independent datasets, the cell cycle gene signature is a more accurate predictor for breast cancer clinical outcome than the previously identified Amsterdam 70-gene signature that has been developed into a FDA approved clinical test MammaPrint.
conclusionTaken together, the gene expression signature model we developed from well defined pathways is not only a consistently powerful prognosticator but also mechanistically linked to cancer biology. Our approach provides an alternative to the current methodology of identifying gene expression markers for cancer prognosis and drug responses using the whole genome gene expression data.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.